Middle East Respiratory Syndrome (MERS) patients have more severe illness and a higher mortality rate than non-MERS severe acute respiratory infection (SARI) patients, according to a study presented at the recent American Thoracic Society (ATS) International Conference 2016 held in San Francisco, California, US.

Benralizumab reduced asthma exacerbations and improved lung function in patients with severe, eosinophilic asthma, according to results of the SIROCCO* and CALIMA** trials which were presented at the European Respiratory Society (ERS) International Congress 2016 held in London, UK.

Chronic obstructive pulmonary disease (COPD) is the fourth cause of global mortality, with experts predicting a potential future rise in the prevalence rates of COPD.
At a recent expert discussion during the Malaysian Thoracic Society (MTS) Congress 2017, Dato' Dr Abdul Razak Abdul Muttalif and Dr Ahmad Izuanuddin provided insights on the current landscape of COPD in Malaysia and the role of dual bronchodilators such as umeclidinium/vilanterol in the management of COPD. Find out more about the use of ANORO® in the treatment of COPD in our upcoming symposium highlight article.

Middle East Respiratory Syndrome (MERS) patients have more severe illness and a higher mortality rate than non-MERS severe acute respiratory infection (SARI) patients, according to a study presented at the recent American Thoracic Society (ATS) International Conference 2016 held in San Francisco, California, US.

Benralizumab reduced asthma exacerbations and improved lung function in patients with severe, eosinophilic asthma, according to results of the SIROCCO* and CALIMA** trials which were presented at the European Respiratory Society (ERS) International Congress 2016 held in London, UK.